Asked by: Will Forster (Liberal Democrat - Woking)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help improve NHS provision of (a) dental care for pregnant women, (b) radiography services for cancer patients, (c) GP access in areas with significant housing developments and (d) audiology services.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
Pregnant women and new mothers are entitled to free National Health Service dental care. The responsibility for commissioning primary care services, including NHS dentistry, to meet the needs of the local population has been delegated to the integrated care boards (ICBs) across England. For the Woking constituency, this is the NHS Surrey Heartlands ICB.
We will get the NHS diagnosing cancer earlier and treating it faster, so more patients survive, and we will improve patients’ experience across the system. We will also be spending £70 million on new radiotherapy machines, to ensure the most advanced treatment is available to the patients who need it.
We are aware of the additional demand and challenges placed upon primary care infrastructure by rapid housing development. We are working closely with the Ministry of Housing, Communities and Local Government to address this issue.
The NHS has a statutory duty to ensure that there are sufficient medical services, including general practices, in each local area, with funding and commissioning reflecting population growth and demographic changes.
Asked by: Will Forster (Liberal Democrat - Woking)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to tackle shortages of ADHD medication in Woking.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Department monitors and manages medicine supply at a national level so that stocks remain available to meet regional and local demand. Information is not collected on a local level. The Department has been working hard with industry and NHS England to help resolve supply issues with some attention deficit hyperactivity disorder (ADHD) medicines, which are affecting the United Kingdom and other countries around the world. As a result of intensive work, some issues have been resolved, and all strengths of lisdexamfetamine, atomoxetine capsules, and guanfacine prolonged-release tablets are now available.
We are continuing to work to resolve supply issues where they remain, for methylphenidate prolonged-release tablets. We are engaging with all suppliers of methylphenidate prolonged-release tablets to assess the challenges faced and their actions to address them. We are also directing suppliers to secure additional stocks, expedite deliveries where possible, and review plans to further build capacity to support continued growth in demand for the short and long-term. We expect supply to improve in the UK throughout December 2024 and January 2025. However, we anticipate supply to be limited for some strengths, and we continue to work with all suppliers to ensure that the remaining issues are resolved as soon as possible. To improve supply chain resiliency, we are also working with prospective new suppliers of methylphenidate prolonged-release tablets to expand the UK supplier base.
We are supporting an ADHD taskforce that NHS England is establishing to examine ADHD service provision. The taskforce will bring together expertise from across a broad range of sectors, including the National Health Service, education, and justice, to help provide a joined-up approach in response to concerns around rising demand. In collaboration with NHS England’s national ADHD data improvement plan, we plan to combine modelling for future growth forecasts, which will be shared with industry to improve demand forecasting for ADHD medicines.
To minimise the impact of the shortages on patients, the Department has worked with specialist clinicians, including those within the NHS, to develop management advice for NHS clinicians to consider prescribing available alternative brands of methylphenidate prolonged release tablets generically, or available alternative ADHD medicines. To support ADHD patients throughout the NHS, we would expect all ADHD service providers and specialists to follow our guidance, which includes offering rapid response to primary care teams seeking urgent advice or opinions for the management of patients, including those known to be at a higher risk of adverse impact because of these shortages.
To aid ADHD service providers and prescribers further we have widely disseminated our communications and continually update a list of currently available and unavailable ADHD products on the Specialist Pharmacy Service (SPS) website, helping ensure that those involved in the prescribing and dispensing of ADHD medications can make informed decisions with patients. The SPS website also offers additional guidance from NHS England specialists to help systems and healthcare professionals manage ADHD supply disruptions.